Cancer and Chemotherapy, Volume III: Antineoplastic Agents is a collection of articles that deals with the treatment of cancer using drugs. The collection describes the various drugs that are used, the therapeutic approaches being taken, and agents that are being developed. Part I is a general review of anti-cancer drugs as regards their action mechanisms, pharmacokinetics, pharmacology, known toxicities, and clinical utility. These drugs include alkylating agents such as mitomycin C and nitrosoureas; plant alkaloids such as maytansine; antibiotics such as anthracyclines; platinum-containing complexes; antimetabolites; and hormones. Part II examines the molecular pharmacology of some major drug classes, namely, bleomycin and anthracycline. The text also discusses the chemistry, mechanism, and any structure-activity relationships found in these drug classes. Part III discusses in detail the clinical pharmacology of some antitumor drugs, for example, cisplatin and nitrosoureas. The text includes the clinical applications, biochemistry, metabolism, and the use of mathematical models in interpreting or describing resulting data. The book is helpful for pharmacologists, molecular biologists, and scientists involved in cancer-research.

List of ContributorsGeneral PrefacePreface to Volume IIIPart I General Reviews 1 Nucleoside Analogues I. Introduction II. Cytosine Arabinoside III. 5-Azacytidin IV. 5-Fluorouracil V. Other 5-Fluoro Pyrimidines VI. 3-Deazauridine VII. Purine Analogs VIII. Arabinosyl Adenine IX. Conclusions References 2 Cyclophosphamide and Analogues I. Introduction II. Structure and Metabolism III. Clinical Pharmacology IV. Toxicities V. Clinical Activity and Dose Schedules VI. Analogues References 3 Nitrosoureas I. Introduction II. Decomposition and Metabolism III. Mechanism of Action IV. Clinical Use V. Clinical Toxicities VI. Discussion References 4 Mitomycin C - An Overview I. Introduction II. Chemistry III. Structure-Activity Relationships IV. Molecular Pharmacology V. Pharmacology VI. Clinical Effects VII. Conclusions References 5 Other Alkylating Agents I. Introduction II. Mechanism of Action III. Other Alkylating Agents IV. Conclusions References 6 The Vinca Alkaloids and Similar Compounds I. The Vinca Alkaloids II. The Podophyllotoxin Derivatives III. Maytansine References 7 Bleomycin - An Overview I. Introduction II. Chemistry III. Molecular Pharmacology IV. Clinical Pharmacology V. Clinical Activities VI. Clinical Toxicities VII. Conclusions References 8 The Anthracyclines I. Introduction II. Chemistry III. Molecular Pharmacology IV. Clinical Pharmacology V. Clinical Activities of Adriamycin and Daunorubicin VI. Toxicities of Adriamycin VII. Anthracyclines in Development References 9 Cisplatin and Analogues: A New Class of Anticancer Drugs I. Introduction II. Antitumor Activity in Animal Tumors III. Animal Toxicology IV. Efficacy V. Toxicity VI. Cisplatin Analogues VII. Conclusion References 10 Investigational Cancer Drugs I. Introduction II. Alkylating Agents III. Anthracycline Analogues IV. Tubulin Binding Agents V. Antitumor Antibiotics VI. Nitrosoureas VII. Antimetabolites VIII. Miscellaneous IX. Summary References 11 Hormone Therapy I. Basis of Endocrine Therapy II. Prostatic Cancer III. Breast Cancer IV. Cancer of the Uterine Endometrium V. Lymphomas VI. Summary References 12 A Human Tumor Stem Cell System: Concepts, Methodology, and Application I. Introduction II. Methodology III. Applications IV. Conclusions ReferencesPart II Molecular Pharmacology of Selected Antineoplastic Agents 13 The Molecular Pharmacology of Bleomycin I. Introduction II. Chemistry III. The Interactions of Metals with Bleomycin and Analogues IV. Effects of Bleomycin on Isolated DNA V. Cellular Effects VI. Effects on the Cell Cycle VII. Morphological Effects VIII. Intracellular Fate and Metabolism IX. Conclusions References 14 Molecular Pharmacology of Anthracycline Antitumor Antibiotics I. Introduction II. Chemistry III. Studies on the Mechanism of Action of Anthracyclines IV. Anthracycline Structure-Activity Relationships V. Conclusions References 15 Vinca Alkaloids: Molecular and Clinical Pharmacology I. Introduction II. Molecular Structure III. Molecular Pharmacology IV. Clinical Pharmacology V. Conclusion References 16 Molecular Pharmacology of Alkylating Agents I. Introduction II. Chemistry of the Alkylating Reactions III. Clinically Effective Alkylating Agents IV. Reactions with Biological Molecules V. Discussion References 17 Molecular Pharmacology of Cisplatin I. Introduction II. Chemistry III. Biochemistry and Mechanism of Action IV. Conclusion References 18 Methotrexate: Molecular Pharmacology I. Introduction II. Chemistry III. Mechanism of Action and Structure-Activity Relationships IV. Transport of Methotrexate and Related Compounds V. Mechanisms of Resistance to Folate Antagonists VI. The Future for Folate Antagonists ReferencesPart III Clinical Pharmacology of Selected Neoplastic Agents 19 Introduction to Clinical Pharmacology I. Introduction II. Pharmacokinetics III. Mathematical Modeling IV. Clinical Correlations of Pharmacokinetics V. Discussion References 20 Clinical Pharmacology of Bleomycin I. Introduction II. Newer Clinical Pharmacological Assays for Bleomycin III. Absorption IV. Distribution V. Elimination VI. Conclusions References 21 Clinical Pharmacology of Cisplatin I. Introduction II. Cisplatin Pharmacokinetics III. Cisplatin Stability IV. Conclusion References 22 Methotrexate: Clinical Pharmacology and Therapeutic Application I. Introduction II. Pharmacology III. Clinical Applications IV. Discussion References 23 Clinical Pharmacology of Nitrosoureas I. Introduction II. Molecular Structure III. Biochemistry and Metabolism IV. Clinical Pharmacology V. Discussion ReferencesIndex